Advanced Cancer Clinical Trial
Official title:
Survival Expectations and Hope Among Cancer Patients at End-of-Life
Literature shows that less than half of advanced cancer patients accurately understand their
prognosis, with most being overly optimistic. Investigators suspect that many patients are
reporting not what they believe, but what they would like to believe. This study aims to
discern patient's beliefs about prognosis independent of hope, to identify factors that
influence patient's beliefs, and to explore patient preferences for prognostic information.
Investigators propose to randomize 200 cancer patients with a prognosis of less than one year
to receive one of the two versions of a survey. Investigators hypothesize that, although many
patients will continue to be overly optimistic about their prognosis, those patients
responding to Version 2, followed by Version 1, will provide more accurate estimates.
Efforts to improve decision making require an understanding of patients' beliefs and
preferences for receiving prognostic information and identifying strategies to clearly convey
that information. This study will fill that gap.
Cancer burden is increasing in Singapore. As Singapore's population increases, so too does
the incidence of cancer. A total of 61,519 incident cancer cases were diagnosed in Singapore
between 2010-2014. High disease incidence has resulted in a greater fiscal burden for
patients and the health system as cancer patients consume a disproportionate amount of
healthcare resources.Despite improved treatments, cancer related mortality is high; cancer
has overtaken diseases of the circulatory system (including ischemic heart disease) to become
the leading cause of death in Singapore. It now accounts for nearly 30% of all deaths. Given
these sobering statistics, policy makers are struggling with how best to cost-effectively
accommodate the health care needs of this vulnerable population.
Many Patients Want to Know Their Prognosis. A recent systematic review showed that the
majority of cancer patients (and their caregivers) expressed a desire for prognostic
information and how it varies by treatment choice. However, the preferred style for receiving
that information varied. One study showed that nearly 80% of patients wanted a qualitative
prognosis (i.e. will they die from the disease) whereas only half wanted a quantitative
prognosis (i.e. how long they will survive). Regardless of how the information is conveyed,
studies have shown that patients who discuss prognosis with their physicians have a better
understanding of the disease trajectory, are more likely to pursue comfort-oriented over
life-prolonging care, and are better able to cope with their illness and clarify priorities
and goals.
Physicians Often Withhold Prognostic Information. Despite many patient's preferences for
prognostic information, the literature reveals a reluctance among physicians' to disclose
information about prognosis when it is poor.8 Physicians often find it easier to offer
aggressive treatments rather than engage in challenging end-of-life discussions.In Singapore,
as with other Asian countries, physicians often collude with caregivers to hide prognostic
information from patients. Even when discussed, patients may fail to understand and recall
the information presented because of unfamiliar terminology, such as "median survival" or
"relative/absolute risk reduction".In many cases, patients are reluctant to ask additional
questions about prognoses even though they may desire this information.
Systematic bias in Prognosis. If lack of communication were the sole cause of poor prognostic
information, then patient's beliefs about their prognosis would be associated with high
variance, but not necessarily biased in a particular direction. Yet, most patients with
advanced cancer state unrealistic expectations about the benefits of treatment, believe that
their cancer is curable and over-estimate their predicted life expectancy.This bias results
from several factors. First, patients who are managing their symptoms well, have strong
social and family support, and/or are happy with other aspects of their care may suffer from
a form of halo effect, which is a cognitive bias where their chances of a cure are positively
influenced by these other properties.Second, patients diagnosed with cancer at early stages
are often (rightly) presented with optimistic chances of survival. For those whose cancer
progresses, even when informed with the new information, they are less likely to fully update
their prior beliefs as compared to someone first diagnosed at a later stage. This lack of
complete updating is consistent with confirmatory bias where people give disproportionately
less consideration to new information that does not conform to their prior
expectations.However, even those newly diagnosed at a later stage are likely to be overly
optimistic about their chances for a cure.Although there are negative consequences from this
form of optimism bias, such as overtreatment, it can also be part of a successful coping
strategy.In fact, the benefits of 'forcing' patients to understand their prognosis may not be
worth the costs due to the additional emotional distress it may inflict. This may hold true
even if hope leads patients to undergo costly and burdensome treatments with a low
probability of success. However, it is still important to understand the extent of divergence
between hope and beliefs, the level and type of information that patients would like to
receive and how best to convey that information.
Discerning Hope from Beliefs. To discern whether or not patients have an accurate
understanding of their prognosis requires disentangling what they believe will occur from
what they hope will occur. There are two promising strategies that allow for producing these
estimates. The first strategy is to ask patients about their own beliefs, and then to compare
their responses to how they believe their physician would respond. If their physician has
provided them with accurate prognostic information, then eliciting the physicians' frame
should allow for a more accurate assessment of beliefs less likely to be confounded by hope.
Consistent with this hypothesis, a study of advanced cancer patients in the US reveals that
the degree of prognostic discordance between physicians and patients decreases when patients
are asked to respond using the physician's frame of reference.Yet, a second study using a
similar approach still found very high discordance, which suggests either poor
patient-physician communication or that using the physician's frame does not entirely reduce
the confounding of hope and beliefs.
A second approach is to offer what economists term 'an incentive compatible strategy.
Consistent with the idea that 'ignorance is bliss', even if patients are aware of their
prognosis, many may prefer to express false hope rather than state the truth about their
condition. In economic terms their utility (a measure of happiness) is higher when they
express false hope. To encourage these individuals to state their true beliefs, they can be
offered a reward such that the utility of expressing their true beliefs plus the reward is
greater than the utility when they express false hope. Because the reward makes it in the
best interest of the participant to reveal his/her beliefs truthfully, such incentive
compatible approaches are sometimes known as truth serums.It is often operationalized by
stating that the reward will be provided if the responses match the views of a professional
(i.e., their physician) or the best evidence from the literature. For example, in one US
study, college students were asked to rank the mortality risk from 12 different causes of
death. Those offered a reward for correct rankings were more likely to rank the mortality
risks accurately for their own age group.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Recruiting |
NCT05045040 -
Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03994601 -
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT01393990 -
A Study of LY2228820 in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02857270 -
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT04121676 -
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03674567 -
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
|
Phase 1/Phase 2 | |
Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A | |
Completed |
NCT02778126 -
A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02529553 -
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT02507544 -
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02245204 -
Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers
|
Phase 1 | |
Terminated |
NCT01929941 -
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT01583777 -
Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
|
Phase 1 |